This content is from: Home

Reverse payment settlement agreements: trading one litigation headache for another

Reverse payment settlement agreements are under scrutiny in the US. Martin B Pavane and Lisa A Ferrari of Cohen Pontani Lieberman & Pavane LLP in New York explain why, and provide advice on how pharmaceutical companies can avoid investigation

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial